

Article type: Original Research Article

Title: Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Authors: Sherko Kuemmel^{1,2*}, Carlo A. Tondini³, Jacinta Abraham⁴, Zbigniew Nowecki⁵, Bartosz Itrych^{6,†}, Erika Hitre⁷, Bogusława Karaszewska⁸, Alejandro Juárez-Ramiro⁹, Flavia Morales-Vásquez¹⁰, Jose Manuel Pérez García^{11‡}, Servando Cardona-Huerta¹², Estefania Monturus¹³, Marco Sequi^{14,15§}, Eleonora Restuccia¹³, Mark Benyunes¹⁶ and Miguel Martín¹⁷

Author affiliations:

¹ Breast Unit, Kliniken Essen-Mitte, Essen, Germany

² Clinic for Gynecology with Breast Center, Charité – Universitätsmedizin Berlin, Berlin, Germany

³ Department of Onco-Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy

⁴ Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK

⁵ Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Centrum Onkologii-Instytut, Warsaw, Poland

⁶ Department of Oncology, Magodent, Warsaw, Poland

⁷ Department of Medical Oncology and Clinical Pharmacology “B”, National Institute of Oncology, Budapest, Hungary

⁸ Przychodnia Lekarska KOMED, Konin, Poland

⁹ Medical Oncology, CME Consultorio de Medicina Especializada, Mexico City, Mexico

¹⁰ FUCAM, Instituto Nacional de Cancerología de Mexico, Mexico City, Mexico

¹¹ Medical Oncology Department, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

¹² Centro de Cáncer de Mama, Hospital Zambrano-Hellion, Tecnológico de Monterrey, Monterrey, Mexico

¹³ Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹⁴ Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland

¹⁵ Biostatistics, PAREXEL, Milan, Italy

¹⁶ Global Product Development, Genentech, Inc., South San Francisco, CA, USA

¹⁷ Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain

*** Corresponding author:** Sherko Kuemmel, MD, PhD

Address: Breast Unit, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany

Telephone: +49-201-174-33001

Email: s.kuemmel@kem-med.com

† Current address: Department of Oncology and Hematology, Central Clinical Hospital MSWiA, Warsaw, Poland (Itrych)

‡ **Current address:** International Breast Cancer Center (IBCC), Quiron Group, Barcelona,
Spain (Pérez García)

§ Current address: CROS Academy, Bologna, Italy (Sequi)

Target journal: *Breast Cancer Research and Treatment*

Online Resource 6 – Prevalence and incidence of baseline and post-baseline ADAs to H SC

	H SC + P IV + D IV (N = 412)
Baseline prevalence of ADAs to H SC	
Baseline evaluable patients	398
Patients with a positive sample at baseline	56 (14.1)
Patients with no positive sample at baseline	342 (85.9)
Post-baseline incidence of ADAs to H SC	
Post-baseline evaluable patients	396
Patients positive for ADAs	95 (24)
Treatment-induced ADAs	82
Treatment-enhanced ADAs	13
Patients indeterminate for ADAs	1
Patients negative for ADAs	300
Treatment unaffected	41
Patients with treatment-induced ADAs	82 (20.7)
Patients with treatment-transient ADAs ^a	42 (51.2)
Patients with treatment-persistent ADAs ^b	40 (48.8)
Median time to onset to ADA, weeks	3.00
ADA titer range	1.00–512.00
ARR by ADA to H SC	
Patients with ADA-negative result post-baseline	300
Patients with ARR	17 (5.7)
Patients with ARR of grade ≥ 3	0
Patients with ADA-positive result post-baseline	95
Patients with ARR	2 (2.1)
Treatment-induced	2 (100.0)
Patients with ARR of grade ≥ 3	0

^a **Treatment-transient ADA:** ADA-positive result detected:

- A) At only one post-baseline sampling timepoint (excluding last timepoint), or
- B) At two or more timepoints during treatment the first and the last ADA-positive samples are separated by a period of less than 16 weeks.

^b **Treatment-persistent ADA:** ADA-positive result detected:

- A) At the last post-baseline sampling timepoint, or
- B) At two or more timepoints during treatment, the first and the last ADA-positive samples are separated by a period of more than 16 weeks

ADA antidrug antibody, ARR administration-related reaction, D IV intravenous docetaxel, H SC subcutaneous trastuzumab, P IV intravenous pertuzumab

Data are number of patients (%) who received subsequent treatment for breast cancer. Percentages are based on the number of the respective category